"On December 16, 2014, the U. S. Food and Drug Administration approved lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroe"...
No proven antidotes have been established for ETOPOPHOS overdosage in humans. In mice, a single intravenous dose of rapidly administered ETOPOPHOS was lethal at or above 120 mg/kg (about 7 times human dose on a mg/m² basis) and was associated with clinical signs of neurotoxicity.
ETOPOPHOS for Injection is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide, etoposide phosphate, or any other component of the formulations.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/11/2016
Additional Etopophos Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.